The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
600mg IV every week and 900mg IV every 2 weeks
Inclusion Criteria: - PNH; - At least 18 years old - Avoid conception; and - Willing and able to give written informed consent
Exclusion Criteria: - Active bacterial infection - Participation in any other drug trial - Pregnant breast feeding, or intending to conceive - Not vaccinated against N meningitidis
Livingston, New Jersey,